Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-11-27
2007-11-27
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C514S012200, C530S350000, C536S023400
Reexamination Certificate
active
11039144
ABSTRACT:
Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a high risk subject comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.
REFERENCES:
patent: 2005/0004027 (2005-01-01), Wiegand et al.
patent: 2006/0172944 (2006-08-01), Wiegand et al.
Phillips, A.J. (2001). The challenge of gene therapy and DNA delivery. J. Pharm. Pharmacol. 53:1169-1174.
Stagner et al. (2004). Beta-cell sparing in transplanted islets by vascular endothelial growth factor. Transplant. Proc. 36:1178-1180.
Yi et al. (2007). VEGF gene therapy for the survival of transplanted fat tissue in nude mice. J. Plast. Reconstr. Aesthet. Surg. 60:272-278.
Palù et al. (1999). In pursuit of new developments for gene therapy. J. Biotechnol. 68:1-13.
de Freitas et al. (2006). Causes and risk factors for graft failure in surgeries performed by physicians in fellowship training. Cornea. 25(3):251-256.
Yatoh, et al., TRANSPLANTATION, vol. 66, No. 11, pp. 1519-1524 (1998).
Cao Jingtai
Cursiefen Claus
Wiegand Stanley
Gregg, Esq. Valeta
Lockard Jon M
Regeneron Pharmaceuticals Inc.
Saoud Christine J.
LandOfFree
Method of treating corneal transplant rejection in high risk... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating corneal transplant rejection in high risk..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating corneal transplant rejection in high risk... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3847803